DEFA14A: XOMA Royalty to Acquire Mural Oncology for $2.035-$2.24/Share

Mural Oncology plc has entered into a definitive agreement to be acquired by XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation, for a cash consideration of $2.035 to $2.24 per share.

Summary

• Mural Oncology plc (MURA) will be acquired by XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation (XOMA), for cash.
• Shareholders are entitled to a base cash price of $2.035 per share.
• An additional cash amount of up to $0.205 per share may be received if Mural's actual closing net cash exceeds the estimated $36.2 million.
• The total consideration per share ranges from $2.035 to a maximum of $2.24.
• The acquisition values Mural's entire issued and to be issued share capital at approximately $36.2 million, excluding any potential additional price per share.
• This represents a 13.1% premium to Mural's closing share price of $1.80 on August 19, 2025, and a 97.6% premium to its undisturbed closing share price of $1.03 on April 14, 2025.
• Mural's Board of Directors has unanimously approved and recommends the acquisition to shareholders.
• The acquisition is expected to close by the end of 2025, subject to shareholder and Irish High Court approvals.
• All outstanding options to acquire Mural Shares held by directors with a strike price above the maximum consideration will be cancelled without payment.

Sentiment

Score: 7

Explanation: The acquisition provides a clear exit strategy and a significant premium for shareholders of a company that has ceased all clinical development, offering certainty of value in a challenging situation. The potential for additional cash based on net cash levels adds a positive, albeit uncertain, upside.

Positives

• Shareholders receive a cash premium of approximately 13.1% over the closing share price on August 19, 2025 ($1.80 to $2.035 base).
• The acquisition offers a significant premium of approximately 97.6% over the undisturbed closing share price of $1.03 on April 14, 2025, prior to the strategic review announcement.
• The transaction provides certainty of cash value for shareholders, avoiding the risks and protracted timeline associated with a voluntary liquidation.
• There is a potential for an additional cash payment of up to $0.205 per share if Mural's actual closing net cash exceeds the estimated $36.2 million.
• Mural's Board of Directors unanimously recommends the acquisition, indicating their belief that it maximizes shareholder value.
• Directors holding approximately 0.42% of outstanding ordinary shares, 1.27% of RSUs, and 4.32% of options have committed to vote in favor of the acquisition.

Negatives

• There is no certainty that the Additional Price Per Share will be paid; it will be zero if actual closing net cash does not exceed the estimated $36.2 million.
• Mural will cease all clinical development of nemvaleukin and undergo an orderly wind-down of substantially all legacy operations post-acquisition, indicating the end of its core business activities.
• Outstanding options with an exercise price equal to or greater than the total consideration will be cancelled without any payment.
• Limited assurances are provided regarding the continuation of existing compensation and employment benefit arrangements for Mural employees following the acquisition.
• The wind-down process includes the potential monetization or disposal of legacy tangible or intangible assets, which Mural previously concluded had limited market opportunity.

Risks

• Uncertainties exist regarding the timing and completion of the Scheme Meeting and Extraordinary General Meeting (EGM).
• Shareholder approval of the acquisition is not guaranteed.
• Closing conditions for the acquisition may not be satisfied or waived, including the failure to receive sanction of the Scheme by the Irish High Court.
• Ongoing costs to Mural could result in its actual closing net cash not exceeding the Estimated Closing Net Cash, leading to no Additional Price Per Share payment.
• General risks and uncertainties pertaining to Mural's business, as described in its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, remain relevant.
• General risks and uncertainties pertaining to XOMA Royalty's business, as described in its most recent filing on Form 10-Q, are also a factor.
• Potential for litigation or regulatory challenges related to the acquisition or the Transaction Agreement.
• The availability of the acquisition to persons not resident in Ireland or the United States may be affected by local laws.

Future Outlook

Mural Oncology will cease all clinical development of nemvaleukin and plans an orderly wind-down of substantially all legacy operations following the acquisition. XOMA Royalty intends to consolidate Mural's corporate functions into its existing operations and will seek to monetize or dispose of substantially all of Mural's legacy tangible or intangible assets.

Management Comments

• Caroline Loew, Ph.D., Chief Executive Officer of Mural, stated: "The Transaction Agreement with XOMA Royalty announced today is the result of a thorough and wide-ranging strategic review process, conducted with the support of our legal and financial advisors. We believe that this transaction, which is supported by our Board, achieves the goal of this strategic review process, which was to maximize shareholder value."
• Owen Hughes, Chief Executive Officer of XOMA Royalty, commented: "XOMA Royalty looks forward to working with Mural to close the transaction as soon as possible."

Industry Context

This acquisition highlights a common trajectory in the biotechnology sector for companies whose primary clinical programs have failed. Mural's decision to discontinue all clinical development of nemvaleukin after disappointing trial results underscores the high-risk nature of drug discovery and development. The acquisition by XOMA Royalty, a biotechnology royalty aggregator, signifies a shift from active R&D to asset monetization and a wind-down of operations, a strategic alternative often pursued to return residual value to shareholders when a company's core pipeline is no longer viable. This transaction reflects the industry's dynamic environment where companies must adapt quickly to clinical outcomes, even if it means exiting the development stage.

Comparison to Industry Standards

• The premium offered (13.1% over recent closing, 97.6% over undisturbed) is a significant return for shareholders of a clinical-stage biotechnology company that has discontinued all its development programs, especially when compared to the potential for further value erosion or the protracted timeline and costs associated with a voluntary liquidation.
• The orderly wind-down and asset disposal strategy is a standard approach for biotech companies facing pipeline failures, aiming to maximize residual value for shareholders rather than incurring further operational burn.
• The cancellation of out-of-the-money options is a common practice in such acquisitions, reflecting the economic reality of the company's valuation post-clinical failure.

Management Changes

Corporate Governance

Legal Proceedings

• Potential shareholder litigation (actual or threatened) against Target, its affiliates, or any of their respective directors, officers, or employees in connection with the Scheme or Acquisition.
• Potential complaints or challenges that may be brought in any court in Ireland (or any other jurisdiction) in connection with the Scheme (or any Takeover Offer), the Transactions, or the Transaction Agreement.

Related Party Transactions

• All of Mural's directors have entered into Irrevocable Undertakings to vote (or procure the vote of) all shares held by them in favor of the Scheme and the Acquisition. These shares comprise approximately 0.42% of outstanding ordinary shares.
• The Irrevocable Undertakings also cover Mural RSUs (approximately 1.27% of outstanding ordinary shares) and options to acquire Mural Shares (approximately 4.32% of outstanding ordinary shares) held by directors.
• All outstanding options to acquire Mural Shares held by the Mural Directors have a strike price above the maximum Consideration payable and will be cancelled without the right to receive any Consideration.

Stakeholder Impact

• **Shareholders**: Will receive a cash premium for their shares, providing a certain exit from a company that has discontinued its core R&D. There is a potential for additional cash based on the company's net cash position.
• **Employees**: Limited assurances regarding the continuation of employment. XOMA Royalty may engage a limited number of Mural employees on a consulting basis solely for the wind-down process, implying widespread job terminations as operations cease.
• **Customers/Suppliers**: The wind-down of Mural's legacy operations will likely lead to the cessation of existing customer and supplier relationships.
• **Creditors**: Contractual obligations and monetary liabilities will be accounted for in the Closing Net Cash calculation, impacting the final additional price per share.

Next Steps

• Mural will prepare, file, and mail a proxy statement (including the Scheme Document) to its shareholders.
• Mural will seek shareholder approval of the Scheme and the Acquisition at a Scheme Meeting and an Extraordinary General Meeting (EGM).
• The Irish High Court must sanction the Scheme.
• An office copy of the Court Order must be delivered to the Irish Registrar of Companies.
• The acquisition is expected to close by the end of 2025.
• Payment of consideration to shareholders will occur within 14 days following the Effective Date.
• Payment of Option Consideration and RSU Cash Consideration will be made as soon as practicable after Completion (no later than 14 Business Days after the Effective Time).
• Mural's securities will be delisted from Nasdaq and deregistered under the Exchange Act.
• An orderly wind-down of substantially all of Mural's legacy operations will commence post-acquisition.
• Mural's corporate functions will be consolidated into XOMA Royalty's existing corporate functions.
• Mural's existing corporate lease will be assigned, sub-leased, or terminated.

Key Dates

Recommendation

The acquisition offers a significant premium over the undisturbed share price, providing a favorable exit for shareholders given the company's decision to cease all clinical development programs. For existing shareholders, holding until the acquisition closes is prudent to realize the offered cash value. The potential for an additional cash amount adds a slight, albeit uncertain, upside. For new investors, the upside is limited to this potential additional cash, making a 'buy' recommendation less compelling unless the additional cash is highly probable and significant.

Keywords

Mural Oncology, XOMA Royalty, Acquisition, Biotechnology, Immuno-oncology, Merger, Cash Offer, Shareholder Value, Strategic Review, Nemvaleukin, Clinical Development, Wind-down